Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Skye Bioscience, Inc. Common Stock(SKYE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SKYE
09/24/2026: SKYE (1-star) is currently NOT-A-BUY. Pass it for now.
Skye Bioscience is a clinical-stage biotechnology company focused on developing therapies for metabolic and eye-related diseases, most notably through its CB1-targeting candidate, Nimacimab. Its core business strength lies in its strategic focus on the high-growth obesity market, offering a potential alternative to current weight-loss solutions. The company's primary growth opportunity centers on positive clinical trial results that could facilitate partnerships or acquisition. Investors face significant risks, including binary clinical outcomes, high cash burn, and intense competition from entrenched industry leaders. This stock is best suited for growth-oriented investors with a high risk tolerance who are closely monitoring clinical trial milestones and management's capital allocation strategy.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward play on clinical trial outcomes rather than a stable growth company. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience significant moves based on news cycles or data readouts, attracting momentum interest. |
| Value investor | Weak fit | Lack of earnings and product revenue makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | Biotechnology development carries inherent volatility and binary risk that is unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks are prone to large price swings based on trial results and regulatory news. |
| Valuation risk | High | Valuations are speculative and depend heavily on future success that is not guaranteed. |
| Competition risk (metabolic drug market) | High | Incumbent players have massive resources and entrenched market positions. |
| Business quality | Medium | The company relies on its ability to execute clinical programs effectively. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Failure at any stage of the clinical pipeline could jeopardize the business viability. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -27.22% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.97M USD | Price to earnings Ratio - | 1Y Target Price 68 |
Price to earnings Ratio - | 1Y Target Price 68 | ||
Volume (30-day avg) 794.5K shares | Beta 2.9 | 52 Weeks Range 0.26 - 4.99 | Updated Date 09/24/2026 |
52 Weeks Range 0.26 - 4.99 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.69 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial candidates including Nimacimab. | The company does not currently generate product revenue and relies on potential future drug approvals. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2.31M | Price to Sales(TTM) 117.9 |
Enterprise Value -2.31M | Price to Sales(TTM) 117.9 | ||
Enterprise Value to Revenue 220.74 | Enterprise Value to EBITDA -2.56 | Shares Outstanding 4.43M | Shares Floating 2.81M |
Shares Outstanding 4.43M | Shares Floating 2.81M | ||
Percent Insiders 4.24 | Percent Institutions 43.73 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Skye Bioscience, Inc. Common Stock
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2015-04-02 | President, CEO & Director Mr. Punit S. Dhillon B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://skyebioscience.com |
Full time employees 2 | Website https://skyebioscience.com | ||
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.